FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of an anti-HER2 antibody and an anti-HER2 antibody conjugate and a low molecular weight medical device, and can be used in medicine. Resulting antibody and its conjugate, as well as a pharmaceutical composition based on them, are used for the treatment and prevention of cancer. Polynucleotide, a combination of polynucleotides and expression vectors are also contemplated. In addition, the use of an antibody and pharmaceutical compositions in the preparation of a medicament for the treatment or prevention of cancer is described.
EFFECT: invention allows the preparation of an anti-cancer drug targeting HER2 for patients with overexpressing HER2 tumors or other relevant HER2-expressing relevant diseases that do not or have a weak response to therapy with Herceptin.
18 cl, 18 dwg, 6 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN THE TREATMENT OF UROTHELIAL CARCINOMA | 2019 |
|
RU2750817C1 |
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
| ANTIBODY-DRUG CONJUGATE LOADED WITH BINARY TOXINS AND ITS USE | 2021 |
|
RU2795148C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| ANTIBODIES AND IMMUNOCONJUGATES RENDERED BY IMMUNO-POSITRON EMISSION TOMOGRAPHY, METHODS OF APPLICATION | 2011 |
|
RU2613886C2 |
| MODIFIED ANTIBODIES LINKED WITH MOTIF INCLUDING CYSTEINE ??RESIDUE, CONJUGATES OF SAID MODIFIED ANTIBODY WITH DRUG SUBSTANCE AND METHODS OF PRODUCING SAME | 2013 |
|
RU2582259C2 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
